Research
Hormonal
Type 2 diabetes pathogenesis requires the concurrent presence of both insulin resistance and beta-cell dysfunction, as neither defect alone is typically sufficient to cause overt glucose intolerance.
Managing Type 2 Diabetes requires addressing both how your body uses insulin (resistance) and how much insulin your pancreas can produce (secretion). Lifestyle changes that improve insulin sensitivity (like exercise and weight loss) are crucial, but they may not be enough if beta-cell function has significantly declined, often requiring medical intervention to support secretion or sensitivity.
StrongSupportsHIGH confidence
Insulin resistance alone is, in most instances, insufficient to cause overt glucose intolerance. To observe the development of frank diabetes mellitus, a defect in insulin secretion must be superimposed on insulin resistance.
Why this rating
Based on a comprehensive review of multiple studies including UKPDS and clamp studies.
Source
PATHOPHYSIOLOGY OF TYPE 2 DIABETES
A J Scheen · Acta Clinica Belgica · 2003
DOI 10.1179/acb.2003.58.6.001
narrative_reviewCited 257×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Visceral adiposity and ectopic fat storage (in liver, muscle, and pancreas) drive insulin resistance and beta-cell dysfunction through mechanisms involving elevated NEFA, lipotoxicity, and adipocytokine secretion.Good
- Adipose tissue acts as an endocrine organ secreting adipocytokines (e.g., TNF-alpha, resistin, adiponectin) that modulate insulin sensitivity and beta-cell function.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →